Institutional members access full text with Ovid®

Share this article on:

IMMUNE RESPONSE AND ONE-YEAR ANTIBODY PERSISTENCE AFTER A FOURTH DOSE OF A NOVEL HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS SEROGROUPS C AND Y-TETANUS TOXOID CONJUGATE VACCINE (HibMenCY) AT 12 TO 15 MONTHS OF AGE

Marshall, Gary S. MD*; Marchant, Colin D. MD†; Blatter, Mark MD‡; Aris, Emmanuel PhD§¶; Boutriau, Dominique MD§¶; Poolman, Jan T. PhD§¶; Friedland, Leonard R. MD§¶; Miller, Jacqueline M. MD§¶

Pediatric Infectious Disease Journal: May 2010 - Volume 29 - Issue 5 - pp 469-471
doi: 10.1097/INF.0b013e3181cdd379
Brief Reports

A total of 236 infants received a fourth Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) dose at 12 to 15 months. One month later, the proportion with anti–PRP antibody ≥1.0 μg/mL and bactericidal titers ≥1:8 to MenC and MenY was 98.9%, 96.9%, and 95.4%, respectively. One year later, anti-PRP concentrations ≥0.15 μg/mL, and MenC and MenY bactericidal titers ≥1:8 persisted in 100%, 96.6%, and 83.8%, respectively. The safety profile of HibMenCY was comparable to Hib.

From the *Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY; †Department of Pediatrics, Boston University Medical Center, Boston, MA; ‡Primary Physicians Research, Pittsburgh, PA; §GlaxoSmithKline Biologicals, King of Prussia, PA; and ¶GlaxoSmithKline Biologicals, Rixensart, Belgium.

Accepted for publication November 13, 2009.

Supported by funds from GlaxoSmithKline Biologicals in all stages of the study conduct and analysis, also involving development and the publishing of the present manuscript.

Conflict of interest: Drs Marchant, Marshall, and Blatter are principal investigators in studies funded by GlaxoSmithKline Biologicals. Drs Aris, Boutriau, Friedland, Miller and Poolman are employees of GlaxoSmithKline Biologicals. Drs Boutriau, Friedland, Miller and Poolman report ownership of stock options. In addition, Drs Poolman and Boutriau declare that they are designated inventor on a variety of patents owned by GlaxoSmithKline Biologicals. Dr Marshall also has been an investigator on clinical trials funded by Merck, Novartis, and Sanofi Pasteur, and he has received honoraria from these companies as well as GlaxoSmithKline for lectures and service on advisory boards. Dr Blatter has participated in research trials with Sanofi Pasteur, GlaxoSmithKline, Novartis, MedImmune, MSD, CSL and Wyeth. He is on the speakers' bureau and has served on advisory boards for GlaxoSmithKline and Sanofi. Dr Colin D. Marchant discloses that he receives grant/research support from GlaxoSmithKline and is participating in an Advisory Board. Dr Marchant is also a consultant for GlaxoSmithKline and Sanofi Pasteur, a clinical investigator for GlaxoSmithKline and Merck, and is on the speaker's bureaus for GlaxoSmithKline and Sanofi Pasteur.

G.S.M. had full access to the data and was responsible for submitting the manuscript for publication.

Address for correspondence: Gary S. Marshall, MD, Department of Pediatrics, University of Louisville School of Medicine, 571 S. Floyd St., Suite 321, Louisville, KY 40202. E-mail: gsmars01@louisville.edu.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).

© 2010 Lippincott Williams & Wilkins, Inc.